R. M. Huber (Munich, Germany), A. Meert (Brussels, Belgium)
Truth telling to lung cancer diagnosed patients and expectations for taking responsibility at treatment
S. Boga, T. Morali, C. Ulman, A. Kant, H. Turker (Istanbul, Turkey)
|  |
Missed in-hospital requested abnormal chest x-rays leading to delay in lung cancer diagnosis: an audit
K. U. Toori, R. K. Kedia, M. D. Winson (Crewe, United Kingdom)
|  |
The use of taped consultations at a regional lung cancer clinic
C. Haslop, T. Win, C. M. Laroche, D. Gilligan (Cambridge, United Kingdom)
| |
A multicenter randomized phase III-trial with carboplatin (C) and paclitaxel (P) in advanced NSCLC: preliminary results of dose adjusted weekly schedule, compared to standard regime (q3w)
C. Schumann, W. R. Guschall, I. Dittrich, D. Ukena, W. Schütte (Ulm, Lostau, Homburg, Halle-Dölau, Germany)
| |
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97
R. M. Huber, M. Flentje, H. Gosse, B. Poellinger, M. Schmidt, J. Willner, K. Ulm, BROCAT Group (Munich, Wuerzburg, Leipzig, Germany)
| |
Combination gene therapy with conditionally replicating adenovirus and adenovirus-p27 of lung cancer
C. T. Lee, C. G. Yoo, Y. W. Kim, S. K. Han, Y. S. Shim, D. P. Carbone (Seongnam, Seoul, South Korea; Nashville, United States Of America)
| |
Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer
Y. C. Kim, K. S. Kim, Y. I. Kim, S. C. Lim, C. M. Park, K. J. Na, S. J. Ahn, K. O. Park (Kwangju, South Korea)
|  |
Compassionate-use gefitinib in non–small cell lung cancer (NSCLC): results from a US expanded access program (EAP)
J. Ochs, J. Grous, K. Warner (Wilmington, United States Of America)
| |